PATRICIA TYLER: Open Payments
NPI 1861603128 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,004 in 43 payments from 11 companies in 2025. Trend: 2023 $1,865 · 2024 $782 · 2025 $1,004
Food & beverage: $1,004
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 16 | $385 |
| Otsuka America Pharmaceutical, Inc. | 11 | $285 |
| Neurocrine BioSciences, Inc. | 5 | $130 |
| ABBVIE INC. | 3 | $46 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| Corium, LLC | 1 | $22 |
| Lundbeck LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
Products named: COBENFY, REXULTI, INGREZZA, VRAYLAR, Qelbree, FANAPT, CAPLYTA, Azstarys.
Industry payments across AL — which companies pay providers there.
